Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Sandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet familiar experience through increased convenience and reduced injection volumeRecommendation further supports expansion of Sandoz biosimilar immunology portfolio in Europe Basel, January 30, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee fo